Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.